Key Takeaways:
- Insmed stops Brinsupri development for hidradenitis suppurativa (HS).
- The drug failed a Phase IIb study, underperforming the placebo.
- The failure is expected to negatively impact INSM stock price.
Back
Back
Insmed halts skin drug trial after Phase 2b failure
Insmed said on April 8 it is ending development of its drug Brinsupri for a skin disease after it failed a Phase 2b study.
"The study did not meet its primary endpoint, with the placebo arm demonstrating a greater clinical response than the treatment arm," the company said in a statement.
The trial was evaluating Brinsupri in patients with moderate-to-severe hidradenitis suppurativa, a chronic inflammatory skin condition. The company noted there were no safety concerns with the drug despite the lack of efficacy.
The discontinuation removes a potential future revenue source from Insmed's mid-stage pipeline. This failure may lead investors to reassess the valuation of the company's other research and development programs.
The trial failure is a significant setback for Insmed's clinical pipeline. Investors will be closely watching the company's next earnings report for updates on its remaining drug candidates.
This article is for informational purposes only and does not constitute investment advice.
Features
Resources
© 2026 Finture Development Limited. All rights reserved